KDM5B and cancer: Strikingly, in two hormone-driven cancers, breast (Supplementary Figure 2A) and prostate (Supplementary Figure 2B) cancers, we observed prevalent KDM5B genomic amplifications, which were accompanied by increased KDM5B mRNA expression in invasive breast cancer (BRCA; Supplementary Figure 1B), or increased (Figure 1A–1C) or an increased trend of (Supplementary Figure 1B) KDM5B mRNA levels in PCa.